Undergraduate education

Washington University in St. Louis, BA, 2001

Years in MSTP



Cellular and molecular biology, 2008


Shigeki Miyamoto, PhD

Thesis title

Proteasome inhibitor resistant NF-kappaB activity in multiple myeloma


Radiation oncology, Washington University, 2011-2015

Current position

Assistant professor, Department of Radiation Oncology, Washington University in St. Louis, School of Medicine

View profile

Undergraduate or masters publications

Mishra MV, Bisht KS, Sun L, Muldoon-Jacobs K, Awwad R, Kaushal A, Nguyen P, Huang L, Pennington JD, Markovina S, Bradbury CM, Gius D. DNMT1 as a molecular target in a multimodality-resistant phenotype in tumor cells. Mol Cancer Res. 2008 Feb;6(2):243-9. PMID: 18314485.

Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, Gius D. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res. 2003 Dec 15;63(24):8984-95. PMID: 14695217.

Karimpour S, Lou J, Lin LL, Rene LM, Lagunas L, Ma X, Karra S, Bradbury CM, Markovina S, Goswami PC, Spitz DR, Hirota K, Kalvakolanu DV, Yodoi J, Gius D. Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation. Oncogene. 2002 Sep 12;21(41):6317-27. PMID: 12214272.

Bradbury CM, Markovina S, Wei SJ, Rene LM, Zoberi I, Horikoshi N, Gius D. Indomethacin-induced radiosensitization and inhibition of ionizing radiation-induced NF-kappaB activation in HeLa cells occur via a mechanism involving p38 MAP kinase. Cancer Res. 2001 Oct 15;61(20):7689-96. PMID: 11606413.

Wei SJ, Botero A, Hirota K, Bradbury CM, Markovina S, Laszlo A, Spitz DR, Goswami PC, Yodoi J, Gius D. Thioredoxin nuclear translocation and interaction with redox factor-1 activates the activator protein-1 transcription factor in response to ionizing radiation. Cancer Res. 2000 Dec 1;60(23):6688-95. PMID: 11118054.

PhD publications

Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, Hematti P, Go R, Hegeman R, Longo W, Williams E, Asimakopoulos F, Miyamoto S. Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemother Pharmacol. 2014 Oct;74(4):875-82. PMID: 25168296; PMCID: PMC4175433.

Markovina S, Callander NS, O'Connor SL, Xu G, Shi Y, Leith CP, Kim K, Trivedi P, Kim J, Hematti P, Miyamoto S. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Mol Cancer. 2010 Jul 6;9:176. PMID: 20604947; PMCID: PMC3095250.

Simonson WT, Markovina S, Grossman WJ, Lokuta MA, Doan AT, Seroogy CM, Huttenlocher A. Common variable immunodeficiency with regulatory T-cell deficiency treated with rapamycin. Ann Allergy Asthma Immunol. 2009 Feb;102(2):170-1. PMID: 19230472.

Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K, Miyamoto S. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res. 2008 Aug;6(8):1356-64. PMID: 18708367; PMCID: PMC2587345.

Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer. 2008 May 19;7:40. PMID: 18489772; PMCID: PMC2408930.

O'Connor S, Markovina S, Miyamoto S. Evidence for a phosphorylation-independent role for Ser 32 and 36 in proteasome inhibitor-resistant (PIR) I-kappa B-alpha degradation in B cells. Exp Cell Res. 2005 Jul 1;307(1):15-25. PMID: 15922723.

Huynh M, Pak C, Markovina S, Callander NS, Chng KS, Wuerzberger-Davis SM, Bakshi DD, Kink JA, Hematti P, Hope C, Asimakopoulos F, Rui L, Miyamoto S. Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma. J Biol Chem. 2018 Feb 16;293(7):2452-2465. PMID: 29279332; PMCID: PMC5818187.